BR112014027676A2 - formulação de cápsula solubilizada de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metóxi-isoquinolin-1-ilóxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletila - Google Patents
formulação de cápsula solubilizada de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metóxi-isoquinolin-1-ilóxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletilaInfo
- Publication number
- BR112014027676A2 BR112014027676A2 BR112014027676A BR112014027676A BR112014027676A2 BR 112014027676 A2 BR112014027676 A2 BR 112014027676A2 BR 112014027676 A BR112014027676 A BR 112014027676A BR 112014027676 A BR112014027676 A BR 112014027676A BR 112014027676 A2 BR112014027676 A2 BR 112014027676A2
- Authority
- BR
- Brazil
- Prior art keywords
- carbamoyl
- ethenylcyclopropyl
- cyclopropylsulfonyl
- isoquinolin
- dimethylpropyl
- Prior art date
Links
- -1 7-chloro-4-methoxy-isoquinolin-1-yloxy Chemical group 0.000 title abstract 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 title abstract 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 title abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 title abstract 3
- 239000007963 capsule composition Substances 0.000 title 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 239000002775 capsule Substances 0.000 abstract 2
- 241000711549 Hepacivirus C Species 0.000 abstract 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 abstract 1
- 229960002118 asunaprevir Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000009246 food effect Effects 0.000 abstract 1
- 235000021471 food effect Nutrition 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643454P | 2012-05-07 | 2012-05-07 | |
| PCT/US2013/038770 WO2013169520A1 (en) | 2012-05-07 | 2013-04-30 | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014027676A2 true BR112014027676A2 (pt) | 2017-06-27 |
Family
ID=48428670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014027676A BR112014027676A2 (pt) | 2012-05-07 | 2013-04-30 | formulação de cápsula solubilizada de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metóxi-isoquinolin-1-ilóxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletila |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US20130302414A1 (https=) |
| EP (1) | EP2846780B1 (https=) |
| JP (1) | JP6276756B2 (https=) |
| KR (1) | KR20150004921A (https=) |
| CN (1) | CN104363899A (https=) |
| AR (1) | AR090954A1 (https=) |
| AU (1) | AU2013260005B2 (https=) |
| BR (1) | BR112014027676A2 (https=) |
| CA (1) | CA2872765A1 (https=) |
| CL (1) | CL2014003012A1 (https=) |
| CO (1) | CO7141457A2 (https=) |
| CY (1) | CY1120756T1 (https=) |
| DK (1) | DK2846780T3 (https=) |
| EA (1) | EA028749B1 (https=) |
| ES (1) | ES2688817T3 (https=) |
| HR (1) | HRP20181583T1 (https=) |
| IL (1) | IL235466B (https=) |
| LT (1) | LT2846780T (https=) |
| MX (1) | MX358545B (https=) |
| MY (1) | MY171378A (https=) |
| NZ (1) | NZ630248A (https=) |
| PE (1) | PE20142439A1 (https=) |
| PH (1) | PH12014502405A1 (https=) |
| PL (1) | PL2846780T3 (https=) |
| PT (1) | PT2846780T (https=) |
| RS (1) | RS57881B1 (https=) |
| SG (1) | SG11201406964QA (https=) |
| SI (1) | SI2846780T1 (https=) |
| SM (1) | SMT201800506T1 (https=) |
| TW (1) | TWI577392B (https=) |
| UY (1) | UY34785A (https=) |
| WO (1) | WO2013169520A1 (https=) |
| ZA (1) | ZA201408967B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2846778B1 (en) * | 2012-05-07 | 2018-04-25 | Bristol-Myers Squibb Holdings Ireland | Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
| EA025560B1 (ru) | 2012-10-19 | 2017-01-30 | Бристол-Майерс Сквибб Компани | Ингибиторы вируса гепатита с |
| WO2014070964A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014071007A1 (en) | 2012-11-02 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914614B1 (en) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2014137869A1 (en) | 2013-03-07 | 2014-09-12 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| JP7433252B2 (ja) | 2018-03-14 | 2024-02-19 | キャンディ・セラピューティクス・リミテッド | Ｎｋ－１／ｎｋ－３受容体二重アンタゴニストを含む新規な医薬製剤 |
| US11464764B2 (en) * | 2018-12-19 | 2022-10-11 | Corcept Therapeutics Incorporated | Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound |
| US12533358B1 (en) | 2025-05-14 | 2026-01-27 | Bayer Consumer Care Ag | Methods of treatment with elinzanetant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| NZ526169A (en) * | 2000-10-31 | 2005-12-23 | Boehringer Ingelheim Pharma | Oral dosage self-emulsifying formulations of pyranone protease inhibitors |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2010042834A1 (en) * | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2013
- 2013-04-29 US US13/872,652 patent/US20130302414A1/en not_active Abandoned
- 2013-04-30 HR HRP20181583TT patent/HRP20181583T1/hr unknown
- 2013-04-30 EP EP13722217.0A patent/EP2846780B1/en active Active
- 2013-04-30 NZ NZ630248A patent/NZ630248A/en not_active IP Right Cessation
- 2013-04-30 MY MYPI2014703294A patent/MY171378A/en unknown
- 2013-04-30 LT LTEP13722217.0T patent/LT2846780T/lt unknown
- 2013-04-30 SM SM20180506T patent/SMT201800506T1/it unknown
- 2013-04-30 KR KR20147033971A patent/KR20150004921A/ko not_active Ceased
- 2013-04-30 WO PCT/US2013/038770 patent/WO2013169520A1/en not_active Ceased
- 2013-04-30 EA EA201492039A patent/EA028749B1/ru not_active IP Right Cessation
- 2013-04-30 SG SG11201406964QA patent/SG11201406964QA/en unknown
- 2013-04-30 PL PL13722217T patent/PL2846780T3/pl unknown
- 2013-04-30 BR BR112014027676A patent/BR112014027676A2/pt not_active IP Right Cessation
- 2013-04-30 AU AU2013260005A patent/AU2013260005B2/en not_active Ceased
- 2013-04-30 CA CA2872765A patent/CA2872765A1/en not_active Abandoned
- 2013-04-30 MX MX2014013220A patent/MX358545B/es active IP Right Grant
- 2013-04-30 ES ES13722217.0T patent/ES2688817T3/es active Active
- 2013-04-30 SI SI201331126T patent/SI2846780T1/sl unknown
- 2013-04-30 PE PE2014001988A patent/PE20142439A1/es not_active Application Discontinuation
- 2013-04-30 JP JP2015511510A patent/JP6276756B2/ja not_active Expired - Fee Related
- 2013-04-30 PT PT13722217T patent/PT2846780T/pt unknown
- 2013-04-30 CN CN201380023724.1A patent/CN104363899A/zh active Pending
- 2013-04-30 DK DK13722217.0T patent/DK2846780T3/en active
- 2013-04-30 RS RS20181141A patent/RS57881B1/sr unknown
- 2013-05-06 AR ARP130101544A patent/AR090954A1/es unknown
- 2013-05-06 TW TW102116102A patent/TWI577392B/zh not_active IP Right Cessation
- 2013-05-06 UY UY0001034785A patent/UY34785A/es unknown
-
2014
- 2014-10-27 PH PH12014502405A patent/PH12014502405A1/en unknown
- 2014-11-03 IL IL235466A patent/IL235466B/en active IP Right Grant
- 2014-11-06 CL CL2014003012A patent/CL2014003012A1/es unknown
- 2014-12-02 CO CO14265249A patent/CO7141457A2/es unknown
- 2014-12-05 ZA ZA2014/08967A patent/ZA201408967B/en unknown
-
2018
- 2018-10-15 CY CY181101051T patent/CY1120756T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014027676A2 (pt) | formulação de cápsula solubilizada de [(1s)-1-{[(2s,4r)-4-(7-cloro-4metóxi-isoquinolin-1-ilóxi)-2-({(1r,2s)-1-[(ciclopropilsulfonil)carbamoil]-2-etenilciclopropil}carbamoil)pirrolidin-1-il]carbonil}-2,2-dimetilpropil]carbamato de 1,1-dimetiletila | |
| BR112014032699A2 (pt) | métodos de tratamento de síndrome metabólica pediátrica | |
| BR112014028841A2 (pt) | processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida | |
| EA201692506A2 (ru) | Ингибиторы репликации вирусов гриппа | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| EA201491299A1 (ru) | Карбаматные соединения, их получение и применение | |
| WO2007138116A3 (de) | Pharmazeutische zusammensetzung zur behandlung von virusinfektionen und/oder tumorerkrankungen durch inhibition der proteinfaltung und des proteinabbaus | |
| UA114726C2 (uk) | 1,4-дизаміщені аналоги піридазину та способи лікування пов'язаних з дефіцитом smn станів | |
| EA201500871A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| EA201300669A1 (ru) | Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение | |
| AU2013311573A8 (en) | Methods of treating Alzheimer's disease and pharmaceutical compositions thereof | |
| EA201200096A1 (ru) | Фармацевтическая композиция ингибитора протеазы вируса гепатита c | |
| HK1198869A1 (en) | Combination treatments for hepatitis c | |
| BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
| BR112015010396A2 (pt) | terapia de combinação | |
| EA201490653A1 (ru) | Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств | |
| WO2014165607A3 (en) | Aromatic-cationic peptide formulations, compositions and methods of use | |
| WO2015038533A3 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| EA201690005A1 (ru) | Состав с модифицированной кинетикой высвобождения | |
| WO2015048503A3 (en) | N-arylmethyl sulfonamide negative modulators of nr2a | |
| MX350145B (es) | Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. | |
| WO2012103282A3 (en) | Methods and compositions for treating alzheimer's disease | |
| EA201390844A1 (ru) | Комплексный состав, содержащий гидрохлорид лерканидипина и валсартан, и способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B25D | Requested change of name of applicant approved |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED (C Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED (CH) |
|
| B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED CO Free format text: RETIFICACAO DO DESPACHO (25.4) ? ALTERACAO DE NOME PUBLICADO NA RPI NO 2517, DE02/04/2019, QUANTO AO ITEM (71) - DEPOSITANTE.ONDE SE LE: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITEDLEIA-SE: BRISTOL-MYERS SQUIBB HOLDINGS IRELAND UNLIMITED COMPANY |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021. |